https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-22 08:33:282024-10-22 08:33:28Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-22 08:33:282024-10-22 08:33:28Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-17 08:37:152024-10-17 08:37:154SC publishes Q3 2024 report
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-16 08:33:382024-10-16 08:33:38AMSilk Announces Successful Partnership Negotiation with Ajinomoto for Industrial Fermentation
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-16 08:30:052024-10-16 08:29:08Biocomposites invests in InfectoTest GmbH – developers of a bacterial-specific point-of-care test for periprosthetic joint infection (PJI)
https://www.optimumcomms.com/wp-content/uploads/2024/04/Template_Logo_300x180px-80x80Web_Logos-7.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-15 08:39:522024-10-15 08:41:35Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-11 11:49:432024-10-11 11:49:43Novo Holdings to acquire majority stake in Stingray Marine Solutions, a leading provider of aquaculture technology
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-10 11:51:312024-10-11 11:51:45Novo Holdings Launches Portfolio Company Booster Therapeutics to Advance New Class of Small Molecule Proteasome Activator Therapeutics
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-10 07:31:072024-10-10 07:31:41Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-09 09:21:572024-10-09 09:21:57STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-09 08:41:502024-10-09 08:41:50Antag Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Lead Molecule, AT-7687
https://www.optimumcomms.com/wp-content/uploads/2023/02/CurveTx_Logo_300x180px-80x80-Recovered.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-09 08:37:022024-10-09 08:37:02Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer
https://www.optimumcomms.com/wp-content/uploads/2023/06/adcendo_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-08 08:36:272024-10-08 08:36:27Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-03 07:41:032024-10-03 07:44:16Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment
https://www.optimumcomms.com/wp-content/uploads/2024/10/Loqus23_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-02 08:43:262024-10-02 10:27:03LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease
https://www.optimumcomms.com/wp-content/uploads/2023/02/CurveTx_Logo_300x180px-80x80-Recovered.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-02 08:39:572024-10-02 08:39:57Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-01 17:00:442024-10-01 17:00:44Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One PatientWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
